Navigation Links
Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
Date:5/21/2008

ith gluten or gluten placebo during a 14 day period. Four doses of the oral formulation of larazotide acetate, all less than 10 mg, were given prior to each gluten challenge. Study endpoints included intestinal permeability (IP), measured as lactulose-mannitol ratio (LAMA), as well as patient signs and symptoms and outcomes, measured by the Gastrointestinal Symptoms Rating Scale (GSRS; validated in several gastrointestinal diseases) and the Psychological General Well-Being Index (PGWBI).

Clinical Findings:

* In the primary study outcome, the prevention of increase in LAMA ratio

from Day 0 to Day 14, the treatment groups showed a dose dependent

protection from increase in intestinal permeability as measured by LAMA

ratio versus placebo, however the difference was not statistically

significant

* In the highest dose active treatment groups of 4 and 8 mg, the LAMA

ratio did not increase after gluten exposure when compared with placebo

* Post-hoc analysis of change in LAMA ratio from Day 7 to Day 21 showed

dose dependent prevention of increase in LAMA across the 4 and 8 mg

treatment groups

* Changes in PGWBI scores and anti-tTG titers were not significant over

the time course of this study

* An unexpected enrollment effect resulted in a fall in intestinal

permeability from Day 0 to Day 7 across all groups suggesting the need

for a run-in period

* Larazotide acetate conferred protection from gastrointestinal symptoms

as measured by the GSRS as well as from expected signs and symptoms of

gluten toxicity

* Follow-up studies of longer duration are currently ongoing

Safety:

* There was no difference in rate of adverse events between Placebo and

Active Drug Groups (46% vs. 55%)

* No Serious Adverse Events (SAEs) were reported

* Headache was the most common AE (reported by
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
2. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
3. PacificGMP Completes GMP Product Fill for Trius Therapeutics
4. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
5. Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
6. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
7. PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
8. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
9. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
10. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
11. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)...  Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) today ... UBS Global Healthcare Conference in New York ... at 11 a.m. Eastern Time. To listen to the ... the Investor Relations section of the Company,s Web site at ... days after the event. About Orexigen® Therapeutics ...
(Date:5/17/2013)... May 17, 2013 /PRNewswire-iReach/ -- United Medical Education, a ... Support (ACLS), Pediatric Advanced Life Support (PALS) and Basic ... and ACLS online course manuals. In order ... need to build an account with the company. By ... programs, United Medical Education is setting a precedent among ...
(Date:5/17/2013)... , Puerto Rico , May 17, ... central and western Puerto Rico , Caribbean ... PR) Center has improved its radiation therapy capabilities with the ... Puerto Rico . Versa HD offers clinicians ... range of tumors throughout the body, while also enabling treatment ...
Breaking Medicine Technology:ACLS Online Course Manuals are Now Available at No Cost through United Medical Education 2Puerto Rico's Caribbean Imaging and Radiation Therapy Center Orders Elekta's New Versa HD System for Treatment of Cancer Patients 2
... Oct. 7 Today the Roskamp Institute said that it ... trials of RCP-006, a compound found in tobacco, for the ... Creek Pharmaceuticals, a subsidiary of Star Scientific in Virginia, and ... In laboratory tests with cells, the compound, ...
... NEW YORK, Oct. 7 Pfizer Oncology will ... approaches to researching treatments for patients with rare ... at the 35 th European Society for ... October 8-12.   (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) ...
Cached Medicine Technology:Roskamp Institute to Begin Human Alzheimer's Clinical Trials With a Natural Compound in Tobacco 2Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 2Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 3Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 4Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 5Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 6Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 7Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 8Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 9Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 10Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 11Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 12
(Date:5/18/2013)... a few extra cups of coffee each month might ... known as primary sclerosing cholangitis (PSC), a new study ... Minn., found that drinking coffee was associated with a ... to cirrhosis of the liver, liver failure and biliary ... relationship. "While rare, PSC has extremely detrimental ...
(Date:5/18/2013)... Orlando, FL (May 18, 2013) There are ... procedures commonly used to diagnose or treat gastrointestinal ... Week (DDW). , A study by New ... that more objective testing may substantially reduce the ... (GERD). Although GERD is believed to affect nearly ...
(Date:5/18/2013)... May 18, 2013 Assisted living ... comes to safety and comfort of their residents. ... provides clients with an effective and cost-efficient solution ... is an integrated, turnkey communications solution that helps ... allowing residents independence and privacy. , The ...
(Date:5/18/2013)... 18, 2013 Transvaginal mesh lawsuits ... to move forward in a consolidated litigation underway in ... reports. According to a notice on the Court’s website, ... mesh litigation will be held on Wednesday, May 22nd. ... filed in the proceeding on behalf of women who ...
(Date:5/18/2013)... “World Healthcare IT Market: Trends & Forecast (2010 – ... and opportunities in North America, Europe, Asia, & Rest ... 89 market data tables , 20 ... , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html , Early buyers will ... IT market is expected to grow from $99.6 billion ...
Breaking Medicine News(10 mins):Health News:Study Links Coffee to Lower Risk for Rare Liver Disease 2Health News:New research identifies practice changes to improve value and quality of GI procedures 2Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 2Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 3Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 2Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 3Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3
... ALAMITOS, Calif., July 7 Traditional medicine,attempts to treat ... underlying causes. As a result, menopausal women may have ... Solutions, a,woman may significantly decrease her menopausal symptoms using ... healing is to remove or reduce all of the ...
... housekeeping enzyme has been found to play a major ... can nurture hematopoietic,stem cells, MEMPHIS, Tenn., July 7 ... as a run-of-the-mill enzyme that helps to,recycle molecules in ... according to St. Jude Children,s Research Hospital investigators., ...
... Children as young as 2 should be tested for high ... In a further concession to the impact of the childhood ... pediatricians is recommending that kids as young as 8 years ... problems later in life. , The American Academy of Pediatrics ...
... July 7 Joel Madden, lead vocalist,for the ... UNICEF,s newest Goodwill Ambassador, officials with the U.S.,Fund ... Sunday during a cable broadcast on global child ... Time, which aired on CNN and,was hosted by ...
... NEW YORK, July 7 Many people ... complication associated with diabetes -- serious gum,disease. ... health and diabetes., Listen to ... Registered journalists can access video, audio, ...
... July 7 iCAD, Inc. (Nasdaq:,ICAD), an industry-leading ... identification of cancer, today announced that the,Company,s second ... open on Thursday, July 31, 2008. iCAD management ... for 10:00 a.m. ET that same,morning., Shareholders ...
Cached Medicine News:Health News:Holistic Health Solutions Offers a Long Awaited Relief for Menopausal Symptoms 2Health News:St. Jude Study Reveals a New Function for an Old Enzyme in Fatal Childhood Disease 2Health News:St. Jude Study Reveals a New Function for an Old Enzyme in Fatal Childhood Disease 3Health News:St. Jude Study Reveals a New Function for an Old Enzyme in Fatal Childhood Disease 4Health News:Pediatricians Recommend Cholesterol Drugs for Some Kids 2Health News:Pediatricians Recommend Cholesterol Drugs for Some Kids 3Health News:Rocker Joel Madden Named Newest UNICEF Goodwill Ambassador 2Health News:iCAD to Host Second Quarter 2008 Financial Results Conference Call on Thursday, July 31, 2008 2Health News:iCAD to Host Second Quarter 2008 Financial Results Conference Call on Thursday, July 31, 2008 3
The Nordt Knot Tightener allows both pushing and spreading of knots, reproducing identical techniques,used when tying traditional open knots. The Nordt Knot Tightener allows tying of any type of s...
... RC Retractor comes with several ... superficial or deep muscle retraction. ... retraction in three different directions: ... The fiber optic light cable ...
Single step suture passage is made simple with Arthro-Pierce instruments. The low profile, highly sharpened tip allows easy passage through tissue in order to retrieve or apply suture....
Soft tissue shoulder retractor system...
Medicine Products: